A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

NCT06163040 · clinicaltrials.gov ↗

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: Elotuzumab in combination with pomalidomide and dexamethasone
DRUG: Elotuzumab in combination with lenalidomide and dexamethasone

Sponsor

Bristol-Myers Squibb